Subtle Medical

Executive Summary

Subtle Medical is a pioneering AI/ML company focused on transforming medical imaging through vendor-neutral deep learning solutions. Its core technology accelerates MRI and PET scans by up to 4-10x while reducing radiation dose, all while maintaining diagnostic image quality. This addresses critical bottlenecks in radiology—long scan times, patient discomfort, and high costs—and improves access to imaging. Subtle Medical’s software integrates seamlessly with existing scanners from any manufacturer, making it highly scalable. The company is well-positioned in the rapidly growing AI diagnostics market, which is projected to exceed $5 billion by 2028. Since its founding in 2017, Subtle Medical has built a strong intellectual property portfolio and established collaborations with leading healthcare institutions. While the company remains private with limited public disclosures, its technology has the potential to become a standard in radiology workflows. Key near-term catalysts include FDA clearance for its latest software version, strategic partnerships with major imaging OEMs, and a Series B funding round to fuel commercial expansion. These events could accelerate adoption and validate its platform, driving significant growth in the coming years.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for SubtleMR 2.0 Acceleration Software80% success
• Q1 2027Strategic Partnership with a Top MRI Manufacturer50% success
• Q4 2026Series B Funding Round of $20M+70% success